Education
About Us
Working with TipRanks
Follow Us
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
TRVI Stock Chart & Stats
$13.70
<$0.01(0.12%)
At close: 4:00 PM EST
$13.70
<$0.01(0.12%)
Day’s Range― - ―
52-Week Range$2.36 - $13.78
Previous CloseN/A
Volume226.18K
Average Volume (3M)2.56M
Market Cap
$1.32B
Enterprise Value$510.02M
Total Cash (Recent Filing)$194.93M
Total Debt (Recent Filing)$823.00K
Price to Earnings (P/E)―
Beta-0.03
Next Earnings
Mar 25, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding121,776,855
10 Day Avg. Volume1,820,513
30 Day Avg. Volume2,561,308
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)4.18
Price to Sales (P/S)0.00
P/FCF Ratio-10.87
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.42K
Enterprise Value/Ebitda-11.15
Forecast
1Y Price Target
$20.89Price Target Upside52.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentTRVI is prepared to submit a full Ph3 draft protocol to the FDA, indicating progress in their development plans.
Financial PerformanceTrevi reported $194.9M in cash and short-term investments, providing a cash runway into 2028.
Market OutlookHaduvio's market opportunity in multiple chronic cough indications is seen as positive, with the stock looking attractive due to a narrowing competitive landscape.
Bears Say
Trevi Therapeutics News
TRVI FAQ
What was Trevi Therapeutics Inc’s price range in the past 12 months?
Trevi Therapeutics Inc lowest stock price was $2.36 and its highest was $13.78 in the past 12 months.
What is Trevi Therapeutics Inc’s market cap?
Trevi Therapeutics Inc’s market cap is $1.32B.
When is Trevi Therapeutics Inc’s upcoming earnings report date?
Trevi Therapeutics Inc’s upcoming earnings report date is Mar 25, 2026 which is in 111 days.
How were Trevi Therapeutics Inc’s earnings last quarter?
Trevi Therapeutics Inc released its earnings results on Nov 13, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.098 by $0.018.
Is Trevi Therapeutics Inc overvalued?
According to Wall Street analysts Trevi Therapeutics Inc’s price is currently Undervalued.
Does Trevi Therapeutics Inc pay dividends?
Trevi Therapeutics Inc does not currently pay dividends.
What is Trevi Therapeutics Inc’s EPS estimate?
Trevi Therapeutics Inc’s EPS estimate is -0.1.
How many shares outstanding does Trevi Therapeutics Inc have?
Trevi Therapeutics Inc has 121,776,855 shares outstanding.
What happened to Trevi Therapeutics Inc’s price movement after its last earnings report?
Trevi Therapeutics Inc reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.098. Following the earnings report the stock price went down -0.785%.
Which hedge fund is a major shareholder of Trevi Therapeutics Inc?
Currently, no hedge funds are holding shares in TRVI
Trevi Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.89 (52.48% Upside)
$20.89 (52.48% Upside)
Hedge Fund Trend
Decreased
By 351.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
232.05%
12-Months-Change
Fundamentals
Return on Equity
-36.87%
Trailing 12-Months
Asset Growth
182.26%
Trailing 12-Months
Company Description
Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
TRVI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, with Trevi Therapeutics reporting successful trial data, financial stability, and strategic plans to expand their market opportunities. Although there were some financial losses and regulatory challenges, the company's advancements and cash reserves suggest a promising outlook.View all TRVI earnings summariesTRVI Stock 12 Month Forecast
Average Price Target
$20.89
▲(52.48% Upside)
Technical Analysis
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Ownership Overview
11.71% Insiders
11.58% Mutual Funds
55.53% Other Institutional Investors
12.54% Public Companies and Individual Investors